Common Mental Disorders Depression - New Zealand Doctor

References
486. Appleby L, Warner R, Whitton A, et al. A controlled study of fluoxetine and
cognitive-behavioural counselling in the treatment of postnatal depression.
Br Med J 1997;314:932–6. [~/x]
487. Honey KL, Bennett P, Morgan M. A brief psycho-educational group intervention
for postnatal depression. Br J Clin Psychol. 2002;41:405–9. [~]
488. Prendergast J, Austin MP. Early childhood nurse-delivered cognitive behavioural
counselling for post-natal depression. Australas Psychiatry 2001;9:255–9. [~/x]
489. Wickberg, Hwang CP. Counselling of postnatal depression: a controlled study on
a population based Swedish sample. J Affect Disord 1996;39:209–16. [~/x]
490. Wisner KL, Hanusa BH, Perel JM, et al. Postpartum depression: a
randomised trial of sertraline versus nortryptiline. J Clin Psychopharmacol.
2006;26(4):353–60. [~/x]
491. Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-reuptake
inhibitors and the risk of birth defects. N Engl J Med 2007;356(26):2675–83.
492. Wogelius P, Norgaard M, Gislum M, et al. Maternal use of selective serotonin reuptake
inhibitors and risk of congenital malformations. Epidemiology 2006;17(6):701–4.
493. US Food and Drug Administration. FDA news. Advising of risk of birth defects with
paxil Ottawa. [cited 24 June 2008]. Available from: http://www.fda.gov/bbs/topics/
NEWS/2005/NEW01270.html.
494. Bérard A, Ramos E, Rey E, et al. First trimester exposure to paroxetine and risk of cardiac
malformations in infants: the importance of dosage. Birth Defects Research Part B:
Developmental and Reproductive Toxicology 2007;80:1827.
495. Einarson A, Pistelli A, DeSantis M, et al. Evaluation of the risk of congenital
cardiovascular defects associated with use of paroxetine during pregnancy.
Am J Psychiatry 2008;165(6):749–52.
496. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to
serotonin reuptake inhibitors. JAMA 2005;293:2372–83.
497. Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after pretnatal exposure
to selective serotonin reuptake inhibitor antidepressants and maternal depression using
population-based linked health data. Arch Gen Psychiatry 2006;63:898–906.
498. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed
in utero to antidepressant drugs. N Engl J Med 1997;336(4):258–62.
499. Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic
antidepressants or fluoxetine throughout fetal life: a prospective, controlled study.
Am J Psychiatry 2002;159(11):1889–95.
500. McElhatton P, Garbis HM, Elefant E, et al. The outcome of pregnancy in 689 women
exposed to therapeutic doses of antidepressants. A collaborative study of the European
Network of Teratology Information services. Reprod Toxicol 1996;10:285–94.
501. Medsafe. Data Sheet: Doxepin. 2004. [cited 24 April 2008]. Available from:
http://www.medsafe.govt.nz/profs/datasheet/a/antencap.htm.
502. Buist A, Janson H. Effect of exposure to dothiepin and northiaden in breastmilk on child
development. Br J Psychiatry 1995;167:370–3.
Identification of Common Mental Disorders and Management of Depression in Primary Care 183